Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

5.010 -0.060 (-1.18%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >

Atea (AVIR) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.

Via The Motley Fool

Topics Earnings

Atea Pharmaceuticals Q2 Earnings Call Highlights ↗

August 12, 2026

Atea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and...

Via MarketBeat

Topics Earnings

Atea Pharmaceuticals Q1 Earnings Call Highlights ↗

May 12, 2026

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no...

Via MarketBeat

Topics Earnings

Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom ↗

May 12, 2026

Via Chartmill

Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Recap: Atea Pharmaceuticals Q4 Earnings ↗

February 28, 2024

Via Benzinga

Atea Pharma (AVIR) Earnings Call Transcript ↗

March 05, 2026

Atea Pharma (AVIR) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗

February 03, 2026

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

Via The Motley Fool

Topics Regulatory Compliance

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗

February 03, 2026

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

Via The Motley Fool

Atea Pharmaceuticals Earnings Preview ↗

February 27, 2024

Via Benzinga

Atea Pharmaceuticals's Earnings Outlook ↗

November 07, 2023

Via Benzinga

Earnings Preview For Atea Pharmaceuticals ↗

August 07, 2023

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 01, 2026

Via Chartmill

Atea Pharma (AVIR) Earnings Call Transcript ↗

November 13, 2025

Atea Pharma (AVIR) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗

November 12, 2025

Atea Pharmaceuticals reports Q3 2025 financials, focusing on its advancing Phase 3 HCV program and pipeline expansion into hepatitis E virus (HEV).

Via Chartmill

Atea Pharmaceuticals Earnings Preview ↗

November 11, 2025

Via Benzinga

Atea (AVIR) Q2 Loss Narrows 8% ↗

August 07, 2025

Via The Motley Fool

Top movers in Wednesday's pre-market session ↗

April 09, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial ↗

March 07, 2025

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.

Via Benzinga

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study ↗

December 04, 2024

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.

Via Benzinga

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus ↗

September 13, 2024

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.

Via Benzinga

Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 13, 2024

Via Benzinga

Earnings Scheduled For March 6, 2025 ↗

March 06, 2025

Via Benzinga

Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus ↗

June 05, 2024

Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.

Via Benzinga

AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024 ↗

May 14, 2024

AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

5 Under 10: Low Share Price, Debt Free, Lots Of Cash ↗

May 13, 2024

A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative.

Via Talk Markets

Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy ↗

January 09, 2024

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗

August 10, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.